TeklaLife Sciences Investors (HQL) Peer Comparison
$20.76
$-0.11
(-0.53%)
As on 02-Sep-2026 12:41EDT
Market cap
$650 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
3.3
P/B Ratio
1.2
Div. Yield
8.4 %
Edit
| TeklaLife Sciences Investors (HQL) | FS KKR Capital (FSK) | Kayne Anderson MLP Investment Closed Fund (KYN) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
650 | 3,291 | 2,474 | 2,089 | 1,892 |
Revenue ($ Mln) |
86 | 948 | 185 | 266 | 205 |
Net Profit ($ Mln) |
85.59 | -375.00 | 490.57 | 314.36 | 254.31 |
Net Margin (%) |
-- | -39.56 | 264.61 | -- | -- |
RoE (%) |
17.59 | -6.75 | 19.67 | 20.33 | 13.09 |
Price to Earnings |
3.33 | -- | 5.06 | 6.56 | 7.24 |
Price-To-Book |
1.23 | 0.65 | 0.94 | 1.22 | 0.98 |
Income Statement ($ Mln)
| TeklaLife Sciences Investors (HQL) | FS KKR Capital (FSK) | Kayne Anderson MLP Investment Closed Fund (KYN) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
86.39 | 1,171.00 | -42.18 | 265.96 | 204.61 |
|
Cost of Revenue
|
4.97 | 356.00 | 23.80 | 20.58 | 8.19 |
|
Gross Profit
|
86.39 | 815.00 | -65.98 | 245.38 | 196.42 |
|
Operating Expenses
|
0.79 | 235.00 | 8.57 | -69.41 | -57.89 |
|
Operating Profit (EBIT)
|
85.59 | 580.00 | -74.55 | 314.79 | 254.31 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
85.59 | 23.00 | -74.55 | 314.36 | 254.31 |
|
Provision for Tax
|
-- | 12.00 | -27.69 | -- | -- |
|
Profit after Tax (Net Income)
|
85.59 | 11.00 | -46.87 | 314.36 | 254.31 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | 11.00 | -- | -- | -- |
Liabilities ($ Mln)
| TeklaLife Sciences Investors (HQL) | FS KKR Capital (FSK) | Kayne Anderson MLP Investment Closed Fund (KYN) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
513.66 | 5,849.00 | 2,332.26 | 1,717.10 | 1,982.80 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
1.01 | 7,880.00 | 880.06 | 18.50 | 2.44 |
|
Current Liabilities
|
0.72 | -- | 10.54 | 17.50 | 2.04 |
|
Total Liabilities
|
515.38 | 13,729.00 | 3,222.86 | 1,753.11 | 1,985.24 |
Assets ($ Mln)
| TeklaLife Sciences Investors (HQL) | FS KKR Capital (FSK) | Kayne Anderson MLP Investment Closed Fund (KYN) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
514.13 | 13,548.00 | 3,222.04 | 1,721.20 | 1,972.27 |
|
Current Assets
|
1.25 | 181.00 | 0.82 | 31.91 | 12.97 |
|
Total Assets
|
515.38 | 13,729.00 | 3,222.86 | 1,753.11 | 1,985.24 |
|
Total Debt*
|
-- | 7,634.00 | 414.96 | 17.50 | -- |
|
Net Current Assets
|
-- | -- | -- | -- | -- |
Cashflow ($ Mln)
| TeklaLife Sciences Investors (HQL) | FS KKR Capital (FSK) | Kayne Anderson MLP Investment Closed Fund (KYN) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-2.32 | 592.00 | 223.53 | -47.75 | -- |
|
Cash Flow from Investing Activities
|
25.21 | 236.00 | -- | 324.34 | -- |
|
Cash from Financing Activities
|
-31.63 | -679.00 | -223.53 | -256.13 | -- |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| TeklaLife Sciences Investors (HQL) | FS KKR Capital (FSK) | Kayne Anderson MLP Investment Closed Fund (KYN) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
17.59 | 0.08 | -1.58 | 20.17 | 13.09 |
|
ROE (%)
|
17.59 | 0.18 | -1.92 | 20.33 | 13.09 |
|
ROA (%)
|
17.54 | 0.08 | -1.38 | 18.21 | 13.07 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
99.08 | 0.94 | 111.12 | 118.20 | 124.29 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| TeklaLife Sciences Investors (HQL) | FS KKR Capital (FSK) | Kayne Anderson MLP Investment Closed Fund (KYN) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.00 | 0.05 | -1.03 | -0.03 | -0.36 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
0.35 | -98.12 | -105.04 | 15.45 | -20.71 |
|
EPS Growth (%)
|
0.00 | -0.98 | -- | -0.42 | -0.21 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| TeklaLife Sciences Investors (HQL) | FS KKR Capital (FSK) | Kayne Anderson MLP Investment Closed Fund (KYN) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
5.23 | 377.07 | -- | 4.94 | 6.87 |
|
Price / Book Value
|
0.87 | 0.71 | -- | 0.91 | 0.88 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
5.23 | 17.44 | -5.57 | 4.90 | 6.87 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| TeklaLife Sciences Investors (HQL) | FS KKR Capital (FSK) | Kayne Anderson MLP Investment Closed Fund (KYN) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-- | 1.31 | 0.18 | 0.01 | -- |
|
Short term debt to equity ratio
|
-- | 0.00 | -- | 0.01 | -- |
|
Current Ratio
|
1.74 | -- | 0.08 | 1.82 | 6.37 |
|
Quick Ratio
|
-- | -- | -- | -- | -- |
|
Interest Coverage
|
-- | 1.05 | -- | -- | -- |
Operating Efficiency Ratios
| TeklaLife Sciences Investors (HQL) | FS KKR Capital (FSK) | Kayne Anderson MLP Investment Closed Fund (KYN) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
1.32 | 35.10 | -1.95 | 0.59 | 6.25 |
|
Asset Turnover
|
0.18 | 0.08 | -0.01 | 0.15 | 0.11 |
|
Receivable days
|
2.89 | 122.27 | -27.00 | 1.18 | 21.00 |
|
Inventory Days
|
-- | -- | -- | -- | -- |
|
Payable days
|
26.55 | 100.03 | -- | 249.67 | 102.43 |
|
Cash Conversion Cycle
|
-- | -- | -- | -- | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
